Journal article
Publication: Planning for rational use of antibiotics in treatment of bovine mastitis in Rwanda
Subclinical mastitis and antimicrobial resistance are a challenge to the dairy industry in many countries particularly in the developing world. A study was conducted between January and February 2015 in five milk shade districts of Bugesera, Nyagatare (Eastern), Gicumbi (Northern), Kamonyi and Nyanza (Southern) provinces in Rwanda to assess the occurrence of subclinical mastitis among smallholder cattle farmers in order to identify the causative bacteria and their antimicrobial susceptibility. Of the 1,188 milk samples screened using the California mastitis test (CMT), 820 (70.6%) tested negative while weak and moderate somatic cell counts (SCCs) occurred in approximately equal proportions at 13% and 12% respectively. Only 42 (3.5%) of the samples were strongly positive. Chi-square tests for homogeneity of SCCs within groups viz parity, quarter which was milked and breed of cow were not significant factors for occurrence of subclinical mastitis (p > 0.05). Among milk samples that were CMT-positive, 496 samples were successfully cultured. There was no bacterial growth in 283 (57 %) milk samples. Bacilli were the most isolated bacterial species (n=94, 19%) while streptococci were the least isolated bacteria (n=10, 3%). The bacteria were most sensitive to Gentamycin (100%) followed by Neomycin and Cotrimoxazole each at 89% but most resistant to Amoxycillin (93%), Streptomycin (68%), Ampicillin (61%) and Tetracycline (61%); there was moderate resistance to Bacitracin. This study showed that subclinical mastitis is still a constraint to milk producers in Rwanda. Since most mastitis cases are likely to be treated before the release of culture and sensitivity laboratory tests, the results from this study showed that single or combination antibiotics comprising Bacitracin, Penicillin, Streptomycin, Ampicillin and Tetracycline may be used as first-line treatment options while Gentamycin, Neomycin and Cotrimoxazole can be used as second-line treatment options in case of failure with first line antibiotics in the treatment of mastitis.
